Simvastatin Effect on Radiation Therapy of Brain Metastases
NCT ID: NCT02104193
Last Updated: 2016-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
50 participants
INTERVENTIONAL
2014-04-30
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective, Multicenter, Observational Cohort Study to Evaluate the Efficacy and Safety of a Novel Anti-tumor Drug As a Radiosensitizer in Patients with Advanced Breast Cancer Brain Metastasis.
NCT06839547
Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer
NCT01942980
Letrozole Plus Metronomic Capecitabine as First-line Treatment for Patients With Recurrent or Metastatic Breast Cancer
NCT04942899
Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer
NCT07021911
Patients With Brain Metastases From HER2-positive Breast Cancer
NCT02135159
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
simvastatin
they will receive simvastatin in addition to radiation therapy
simvastatin in addition to radiation therapy
simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
control
they will receive radiation therapy only
radiation therapy
radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
simvastatin in addition to radiation therapy
simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
radiation therapy
radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age more than 18 years old
* Patients should be planned for radiation therapy
Exclusion Criteria
* Hepatic dysfunction (alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>3 times the upper normal level )
* Pregnancy or lactation.
* Known hypersensitivity to simvastatin
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MAy Ahmed Shawki
teaching assisstant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
May A Shawki, master
Role: PRINCIPAL_INVESTIGATOR
Faculty of Pharmacy- Ain Shams university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams university Hospitals
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PH CL 25
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.